# Nebius crowns the AI that could save lives in healthcare > Introduction: when the AI cloud becomes a medical accelerator - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-04 - Canonical URL: https://mad-max.co/en/article/nebius-couronne-lia-qui-pourrait-sauver-des-vies-en-sante ## Introduction: when the AI cloud becomes a medical accelerator ### An awards ceremony unveiled in London, with global repercussions The Dutch company **Nebius**, listed under the ticker **NBIS** and specializing in cloud infrastructure for **artificial intelligence**, unveiled on **July 1, 2026** in London the winners of the second edition of its **AI Discovery Awards**, an annual competition rewarding young companies that use AI to accelerate breakthroughs in **healthcare** and **life sciences**. According to **Business Wire**, the event gathered dozens of founders, researchers and investors presenting projects ranging from imaging diagnostics to new drug discovery. This initiative, launched for the first time in 2025, illustrates a deep trend the **West** has every interest in encouraging: the convergence of massive computing power and applied biomedical research, at a time when the global race for **artificial intelligence** is intensifying against strategic rivals determined to close their technological gap. ### Five categories, fifteen main winners and expanded global reach Unlike the inaugural 2025 edition, which had four categories, this second edition now has five: **Biopharma**, **Digital Health**, **Genomics**, **Medical Devices** and **Medical Imaging**. Each category crowned three winners, receiving respectively **$100,000**, **$50,000** and **$30,000** in compute and inference credits on the **Nebius AI Cloud** infrastructure. A new and significant development for 2026: **Nebius** also introduced regional prizes called **Regional Trailblazer**, rewarding promising companies in **Africa**, the **Asia-Pacific region**, **Europe**, the **Middle East**, **Latin America** and **North America**, each receiving **$30,000** in additional compute credits. *I find it refreshing to see a technology company expand its competition to regions of the world often overlooked by the usual Silicon Valley ecosystem: this is exactly the kind of inclusive Western outreach that strengthens, rather than weakens, our overall technological edge.* ## The winners redefining imaging diagnostics ### Real Time Imaging Systems and Nucleo Research lead the pack In the **Medical Imaging** category, **Nucleo Research** took first place, followed by **Subtle Medical** and **Hertility Health**. In the **Medical Devices** category, **Real Time Imaging Systems** won first prize, ahead of **BAIBYS Fertility** and **Fluent**, according to the official winners list published by **Nebius**. These technologies, though technically complex, pursue a clear objective: speeding up and improving the reliability of medical diagnosis through algorithms capable of analyzing radiological or pathological images with a precision and speed the human eye alone cannot match, particularly in regions of the world suffering from a shortage of qualified specialists. ### Corti.ai and the quiet revolution in digital health In the **Digital Health** category, **Corti.ai** took first place, ahead of **VitVio** and **EverEx**. These platforms use **artificial intelligence** to transform clinical workflows, notably through automated patient interaction and real-time analysis of medical data, a sector booming since the post-pandemic acceleration of digitization across Western health systems. This category illustrates well the philosophy of the competition: rewarding not only spectacular scientific breakthroughs, but also pragmatic tools capable of immediately improving the daily efficiency of often-overwhelmed medical staff in Western hospitals. *I believe these digital health tools, less media-spectacular than genomics breakthroughs, could nonetheless have the most immediate impact on the daily lives of patients and Western medical staff in the short term.* ## Genomics and biopharma, spearheads of innovation ### Omniscope and Phylo, two ambitious scientific bets The **Genomics** category was won by **Omniscope**, ahead of **Twig Bio** and **DELFI Diagnostics**, while the **Biopharma** category crowned **Phylo** in first place, followed by **Virgo** and **Decoy Therapeutics**. These companies harness the massive computing power provided by **Nebius** to accelerate research processes that historically took years of traditional lab work. The genomics category in particular illustrates the scale of applied AI's transformative potential: mapping complex genetic variations across entire populations is now possible at a speed that would have seemed unrealistic just a decade ago. ### Continuity with the inaugural 2025 edition At the first edition held in June 2025, **Nebius** had already rewarded companies such as **Ataraxis AI**, whose cancer treatment prediction platform achieved accuracy **30%** higher than standard genomic tests, clinically validated on more than **7,500 patients** across **15 institutions**. This continuity between the two editions shows the competition is not a one-off media stunt, but part of a lasting strategy to support biomedical innovation. The number of applications also grew, rising from **257** at the first edition to an expanded pool of international participants for 2026, a tangible sign of the competition's growing credibility within the global health start-up ecosystem. *I find this continuity reassuring: too many technology competitions fizzle out after a heavily publicized first edition, whereas this one instead seems to grow in scale and scientific seriousness year after year.* ## Why compute infrastructure is becoming the backbone of scientific competition ### GPU credits that sometimes matter more than traditional funding For many young life sciences companies, access to sufficient computing power is often a more limiting obstacle than traditional venture capital funding. The compute credits offered by **Nebius**, reaching up to **$100,000** for top places, allow these companies to train large-scale **artificial intelligence** models without devoting a disproportionate share of their limited capital to technical infrastructure. This approach, combining public recognition with concrete material support, sets the **Nebius** competition apart from mere honorary ceremonies: it offers a real, immediately usable competitive advantage to the winning companies in their race against better-funded rivals. ### European infrastructure gaining ground against American giants **Dr. Ilya Burkov**, global head of growth for life sciences and healthcare at **Nebius**, with more than **15 years of experience** spanning clinical medicine, biotechnology and cloud computing, embodies the company's ambition to position itself as a credible European alternative to American **cloud computing** giants. **Nebius** has also recently expanded its presence in the **United Kingdom** with one of the country's first advanced **NVIDIA** infrastructure deployments. This European geographic expansion fits into a broader context in which the **West** is seeking to reduce its excessive dependence on a limited number of AI infrastructure providers, a diversification deemed strategically sound given the growing concentration of the global advanced-computing market. *I believe the European diversification of AI infrastructure, embodied here by Nebius, is a strategically sound development for the West: relying on too small a pool of providers, even allied ones, carries risks that recent global trade tensions have clearly demonstrated.* ## A geopolitical stake disguised as an innovation contest ### The global race for health-applied AI is accelerating Behind the philanthropic facade of this competition lies a broader geopolitical stake: the global race to dominate the application of **artificial intelligence** to human health. **China** is investing massively in this sector, seeking to combine its vast national medical databases with its growing advanced computing capabilities, a strategy that worries several Western analysts regarding data security and biomedical intellectual property. Facing this competition, initiatives like Nebius's strengthen the Western ecosystem's ability to quickly identify and support the most promising innovations, before they are captured or replicated by rival state actors less concerned with Western ethical standards on personal medical data protection. ### Academic partnerships that consolidate the Western ecosystem Several winners and honorable mentions from previous editions of the **Nebius** competition have established partnerships with prestigious academic institutions, including **Microsoft Research** and leading university hospital centers. These collaborations strengthen an integrated Western ecosystem where academic research, venture capital and advanced cloud infrastructure work together rather than in separate silos. This structural integration is, in my view, one of the West's genuine lasting competitive advantages against the more centralized, less collaborative models adopted by certain international technology rivals. *I believe this fluid integration between Western academic research, venture capital and private cloud infrastructure represents a structural advantage our technology rivals still struggle to replicate despite their massive investments.* ## Persistent challenges despite the technological enthusiasm ### Clinical validation before commercial celebration Despite the legitimate enthusiasm sparked by this awards list, it is worth recalling that most of the honored technologies remain at early development stages, still requiring rigorous clinical validation before any large-scale deployment in Western public health systems. Recent history of AI applied to medicine is full of examples of technologies that looked promising in the lab but failed to deliver in broader clinical trials. This methodological caution takes nothing away from the merit of the winning companies, but it usefully reminds us that the path from a prototype honored at a London ceremony to a medical tool actually deployed to millions of patients remains long, costly and strewn with legitimate regulatory obstacles. ### The sensitive question of medical data protection The rapid rise of these technologies also raises legitimate questions about the protection of personal medical data used to train these **artificial intelligence** models. European regulators, already vigilant on these issues through strict regulatory frameworks, will need to continue adapting their oversight mechanisms as these technologies grow in sophistication and widespread clinical adoption. A careful balance between encouraging innovation and rigorously protecting personal data remains essential to preserve Western public trust in these emerging medical technologies, a trust that is itself a competitive advantage our less privacy-scrupulous rivals do not necessarily possess. *I believe this European regulatory vigilance on medical data protection, sometimes criticized as an innovation brake, is actually a long-term trust advantage the West would be wrong to sacrifice to artificially speed up its pace of technological adoption.* ## The role of independent judges in the competition's credibility ### A panel drawn from biotech, pharma and venture capital The competition's scientific credibility rests largely on its panel of independent judges, composed at the inaugural edition of **19 experts** drawn from major biotechnology, pharmaceutical and specialized **venture capital** firms. This diversity of expertise allows applications to be assessed on scientific, clinical and commercial criteria alike, reducing the risk of rewarding projects that look appealing on paper but lack real practical viability. This evaluative rigor sets the **Nebius** competition apart from mere technology public-relations exercises: it reflects a serious intent to identify innovations with genuine clinical impact potential, rather than impressive but sterile technology demonstrations. ### Honorable mentions that widen the talent-spotting net Beyond the main winners, the competition also grants honorable mentions to dozens of additional companies, allowing a much broader pool of emerging talent to be identified than the official podium alone could reflect. This expanded approach benefits the entire ecosystem, even companies not selected among the top three in each category. This relative generosity in talent identification bolsters the competition's reputation among venture capital investors, who now regularly consult the full list of honorable mentions to spot future investment opportunities in the digital health sector. *I find this system of expanded honorable mentions clever: it turns a competition into a genuine mapping tool for global health innovation, well beyond the three official winners in each category.* ## Nebius's expansion, from raw compute to sector specialization ### From a mere GPU provider to a strategic sector partner **Nebius** has profoundly transformed its business positioning over the past two years, moving from a simple provider of raw computing power to a strategic sector-specific partner, with healthcare and life sciences now an explicitly prioritized focus for the company's leadership. This specialization allows **Nebius** to differentiate itself from competitors offering more generalist infrastructure less suited to the specific needs of biomedical research. Client companies such as **Prima Mente**, which develops foundation models to understand the human brain, or **Helical**, which helps pharmaceutical companies accelerate their virtual experiments, concretely illustrate this sector-specialization strategy embraced by **Nebius**. ### An NVIDIA partnership that strengthens the European position **Nebius** announced in March 2026 an expanded partnership with **NVIDIA** aimed at strengthening its large-scale cloud infrastructure dedicated to **artificial intelligence**, a collaboration that further consolidates the company's technical credibility with demanding institutional clients in the healthcare sector. This technical alliance lets **Nebius** offer compute capabilities comparable to those of the largest American providers, while retaining European governance and data centers. This combination of cutting-edge American technology and European governance could prove particularly reassuring for European health companies eager to meet strict regulatory data-protection requirements while benefiting from world-class computing power. *I believe this combination of cutting-edge American technology and rigorous European governance represents exactly the kind of transatlantic balance the West needs to stay competitive without sacrificing its ethical standards.* ## Conclusion: a modest showcase, but an encouraging signal ### What this awards list really reveals about the state of Western innovation Beyond company names still little known to the general public, this **AI Discovery Awards** list reveals a living Western innovation dynamic, geographically diverse and methodologically rigorous. The combination of generous compute infrastructure, validation by an independent panel of judges drawn from biotechnology and finance, and expanded international reach outlines a replicable model other Western technology players would do well to imitate. This dynamic, however modest it may appear compared with the spectacular announcements of American tech giants, illustrates the continued vitality of the Western innovation ecosystem applied to human health. ### A milestone to watch to gauge the winners' real maturation The real test of this competition will play out in the coming years, when observers will be able to measure how many of these honored companies have actually turned their promising prototypes into medical solutions concretely deployed to real patients. The 2025 edition had already identified companies such as **Ataraxis AI**, whose clinical progress deserves close monitoring in the coming months. For now, this 2026 awards list confirms that the **West** retains a real methodological and institutional lead in applying **artificial intelligence** to healthcare, an advantage it will nonetheless need to keep actively cultivating against increasingly determined international competition. *I close this decoding convinced that the real technological battle of the next decade will be fought as much in biomedical labs as in data centers, and that the West has every interest in relentlessly cultivating this kind of initiative.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - [Nebius celebrates healthcare and life sciences innovators at expanded AI Discovery Awards — Business Wire, July 1-2, 2026](https://www.businesswire.com/news/home/20260701168365/en/Nebius-celebrates-healthcare-and-life-sciences-innovators-at-expanded-AI-Discovery-Awards) - [AI Discovery Awards 2026 — Nebius, 2026](https://nebius.com/ai-discovery-award) - [Nebius celebrates healthcare and life sciences — Yahoo Finance, July 2, 2026](https://finance.yahoo.com/healthcare/articles/nebius-celebrates-healthcare-life-sciences-060000618.html) ### Secondary sources - [Nebius has named the winners of its inaugural AI Discovery Awards — Nebius Newsroom, June 2025](https://nebius.com/newsroom/nebius-accelerates-next-generation-of-healthcare-and-life-sciences-innovation-with-inaugural-ai-discovery-awards) - [Cloud for Scientific AI and Healthcare — Nebius](https://nebius.com/solutions/life-sciences-and-healthcare) - [Nebius AI Cloud arrives in UK with advanced NVIDIA infrastructure — MarketScreener, November 2025](https://www.marketscreener.com/news/nebius-ai-cloud-arrives-in-uk-with-one-of-the-countrya-s-first-advanced-nvidia-ai-infrastructure-de-ce7d5cddd188fe21) --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/nebius-couronne-lia-qui-pourrait-sauver-des-vies-en-sante